Clinical Trial Update: Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lenalidomide for high-risk acute myeloid leukemia in remission has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2022-11-14